Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
NANewAmsterdam Pharma Company N.V. logo

NewAmsterdam Pharma Company N.V. (NAMS)

NASDAQ · Currency in USD
$19.71 ▼ -1.87 (-8.67%)
At close: Oct 23, 4:00 PM ET. Market closed.
$19.71 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$21.58
Open
$21.39
Day's Range
$19.13 – $21.39
52 Week Range
$19.13 – $42.21
Volume
2,311,178
Avg. Volume
1,331,764
Market Cap
$2.30B
Beta (5Y Monthly)
0.10
PE Ratio (TTM)
--
EPS (TTM)
-$2.10
Earnings Date
Nov 4, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$51.33

Profile: NewAmsterdam Pharma Company N.V.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
100
CEO
Michael Harvey Davidson Facp.

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease.

Earnings

Next report: Wed, Nov 4, 2026
EPS estimate -$0.49 · Revenue est. $7.54M
DateEst.Actual
Aug 5, 2026-$0.48-$0.52Miss
May 7, 2026-$0.46-$0.40Beat
Feb 18, 2026-$0.43-$0.63Miss
Nov 5, 2025-$0.38-$0.61Miss
Aug 6, 2025-$0.52-$0.15Beat
May 8, 2025-$0.45-$0.49Miss

Analyst view

Consensus price target
$51.33 ▲ +160.4%
Range $45.00 – $58.00
Rating: Buy
Buy 90% · Hold 10% · Sell 0%

Get free alerts on NAMS and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.